News

Vivos Inc. Expands IsoPet Therapy to Exotic Animals Offering Hope

Vivos Inc. Expands IsoPet Therapy to Exotic Animals Offering Hope

Vivos Inc. Expands IsoPet Therapy to Exotic Animals

Vivos Inc. (OTCQB: RDGL) is making significant strides in its innovative approach to cancer treatment with the introduction of IsoPet® Precision Radionuclide TherapyTM for exotic animals. Recently, this pioneering company treated a ferret, achieving promising results that included a notable reduction in tumor size within three weeks. Adult exotic animals often have limited treatment options, and traditional methods like surgical removal can be overly invasive.

Dr. Korenko Highlights Growing Demand

Dr. Michael K. Korenko, President and CEO of Vivos Inc., emphasized the increasing need for effective cancer treatments tailored to a broader range of animals, not just common pets. "While we have experience treating cats, dogs, and horses, the demand for solutions aimed at exotic pets and zoo animals is becoming more pressing. Engaging in conferences helps us raise awareness about IsoPet Therapy as a viable option for treating cancerous tumors," he stated.

What is IsoPet Therapy?

IsoPet® utilizes a state-of-the-art Yttrium-90-based injectable therapy to combat tumors in both animals and humans. By employing proprietary hydrogel technology, this therapy delivers radiation directly to the tumor site. It is designed to manage cancers that are non-resectable or resistant to other forms of radiation, making it a unique solution in the veterinary oncology landscape.

How IsoPet Slashes Treatment Times

One of the remarkable aspects of IsoPet® is its efficient delivery system. Since its short-range beta radiation targets only the tumor area, it minimizes damage to surrounding tissues. In fact, more than 90% of the therapeutic radiation is released within just ten days. This efficiency means that patients can undergo treatment as outpatients, ultimately returning home without elevated radiation concerns for their families.

Past Research and Future Directions

Research conducted at respected university veterinary hospitals confirms the safety and effectiveness of IsoPet® for various cancers. For instance, significant studies concerning feline sarcomas have been completed successfully, paving the way for further use. Following a thorough FDA review, IsoPet® was classified as a medical device, simplifying the pathway for veterinarians to utilize this therapy in practices nationwide and ensuring that animals receive the best possible care.

Synergy between IsoPet and RadioGel®

IsoPet® operates under the same technological principles as RadioGel®, which is applied in human cancer treatments. Although both products use potent Yttrium-90, they are differentiated by unique branding to prevent any mix-up between veterinary and human applications. This strategic decision underscores Vivos Inc.'s commitment to clarity and safety in its therapeutic offerings.

Looking Ahead

As Vivos Inc. forges ahead, it remains focused on expanding its services and enhancing patient care. The shift towards treating exotic animals marks a substantial evolution in their business model, aligning with both the company's mission and the needs of pet owners seeking alternative cancer treatments for their beloved companions.

For inquiries, Michael K. Korenko can be contacted via email at MKorenko@RadioGel.com. Stay updated by following Vivos Inc on X (Twitter) at @VivosIncUSA and the companies Radiogel and IsoPet.

Frequently Asked Questions

What is IsoPet® therapy?

IsoPet® therapy is a precision radionuclide treatment developed by Vivos Inc. to target cancerous tumors in both pets and exotic animals using Yttrium-90.

How does IsoPet® work?

This therapy delivers radiation directly to the tumor via hydrogel technology, leading to effective tumor control while sparing surrounding healthy tissue.

What animals can be treated with IsoPet®?

Initially tailored for common pets like cats and dogs, IsoPet® has expanded to include exotic animals, showcasing its versatility in veterinary applications.

Is IsoPet® safe for pets?

Yes, IsoPet® has been validated through rigorous research, confirming its safety and efficacy in treating various types of tumors in animals.

Who can I contact for more information?

You can reach out to Michael K. Korenko, the CEO of Vivos Inc., via email at MKorenko@RadioGel.com for further inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 25

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 120

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 43

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 52

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Customer Care: Apivia and SoundHound Unite

Updated Category News Views 247

Transforming Customer Service with AI SoundHound AI (NASDAQ: SOUN) has joined forces with Apivia Courtage, a notable entity within France's AEMA Group, which is recognized as a leading mutual insurance organization. This partnership aims to implement agent-based artificial intelligence into Apivia Courtage's customer service systems through the innovative Amelia 7...

Continue Reading
Taiwan's Bold Pedal Into Sustainability: EUROBIKE 2026

Updated Category News Views 40

Stepping Up the Game at EUROBIKE 2026 Ask any veteran cyclist: The road to innovation is a winding one, and Taiwan's Bicycle Industry seems determined to tackle every curve head-on at EUROBIKE 2026. This isn't just about flashy tech; it's a full-blown commitment to smart, low-carbon mobility—a real 'get on the bike or get left behind' moment. Unveiling the AI-Powered...

Continue Reading
TDI Welcomes Jay Truesdale as New Chief Executive Officer

Updated Category News Views 389

TD International Appoints New Leadership TD International LLC (TDI), a prominent strategic advisory and risk intelligence firm, has announced significant leadership changes with the appointment of Jay Truesdale as Chief Executive Officer. This move marks a pivotal moment for TDI, as it looks to leverage Truesdale's considerable expertise in geopolitics and global markets....

Continue Reading
Canaan Inc. Streamlines Focus on Core Cryptocurrency Market

Updated Category News Views 258

Canaan Inc. Streamlines Focus on Core Cryptocurrency Market Canaan Inc. (NASDAQ: CAN) has recently taken a significant step in refining its business operations. The company is discontinuing its non-core AI semiconductor division to concentrate on its core strengths in the ever-evolving world of cryptocurrency. This strategic decision is aimed at enhancing efficiencies and...

Continue Reading
Ascentage Pharma's Impressive Growth in 2025: A Review

Updated Category News Views 567

Overview of Ascentage Pharma's Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) recently announced its interim unaudited financial results for the first half of 2025. The report highlights significant growth, particularly in product sales, and provides exciting updates on ongoing clinical programs and commercial strategies. The company's...

Continue Reading